Stock LIXT LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
2.89 USD +0.27% Intraday chart for Lixte Biotechnology Holdings, Inc. -11.35% +22.98%
23/04 Lixte Biotechnology Files Up to $50 Million Mixed Shelf MT
27/03 Sector Update: Health Care Stocks Advance Late Afternoon MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lixte Biotechnology : Investor Presentation - April 2024
PU
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
AQ
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
AQ
Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
AQ
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
AQ
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
AQ
Lixte Biotechnology : Investor Presentation - November 2023
PU
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
AQ
LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration
AQ
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
AQ
Lixte Biotechnology : Investor Fact Sheet – October 2023
PU
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
AQ
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
AQ
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
AQ
Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
AQ
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
AQ
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
AQ
LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023
AQ
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
AQ
Lixte Biotechnology : 10-Q Filing Q1 2023
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LIXT Stock
  4. News Lixte Biotechnology Holdings, Inc.
  5. Press Releases